UNASSIGNED: @entity41 ( @entity41 ) is highly prognostic in pediatric B-precursor @entity981 ( @entity981 ). In COG High Risk B- @entity981 study AALL0232 we investigated @entity41 in subjects randomized in a 2X2 factorial design to receive either High-Dose ( @entity2033 - @entity6822 ) or Capizzi @entity1499 (C- @entity6822 ) during interim maintenance (IM), or @entity229 or @entity619 during induction. Subjects with end induction @entity41 >=0.1% or those with morphologic slow early response were non-randomly assigned to receive a second IM and delayed intensification phase. @entity41 was measured by 6-color flow cytometry in one of two reference labs, with excellent agreement between the two. Subjects with end induction @entity41 <.01% had a 5y EFS of 87  1% vs 74  4% for those with @entity41 0.01%-0.1%; increasing @entity41 amounts was associated with progressively worse outcome. Subjects converting from @entity41 positive to negative by end consolidation had a relatively favorable 79  5% 5 y DFS vs 39  7% for those with @entity41 >=0.01%. Although @entity2033 - @entity6822 was superior to C- @entity6822 , @entity41 retained prognostic significance in both groups (86  2% vs 58  4% for @entity41 negative vs positive C- @entity6822 subjects; 88  2% vs 68  4% for @entity2033 - @entity6822 subjects). Intensified therapy given to subjects with @entity41 >0.1% did not improve either 5y EFS or @entity3012 . However, these subjects showed an early relapse rate similar to that seen in @entity41 negative ones, with EFS/ @entity3012 curves for @entity1 with 0.1%-1% @entity41 crossing those with 0.01%-0.1% @entity41 at 3 and 4 years, thus suggesting that the intensified therapy altered the disease course of @entity41 positive subjects. Additional interventions targeted at the @entity41 positive group may further improve outcome. NCT00075725 at www.clinicaltrials.gov.

Prognostic significance of minimal residual disease in high risk B- XXXX : a report from @entity1 's Oncology Group study AALL0232.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity981 :: ('MESH:D054198', 'Disease') :: ['ALL', 'acute lymphoblastic leukemia'] @entity41 :: ('MESH:D018365', 'Disease') :: ['MRD', 'Minimal residual disease'] @entity3012 :: ('MESH:C567932', 'Disease') :: ['OS'] @entity6822 :: ('D008727', 'Chemical') :: ['MTX'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['Prednisone'] @entity2033 :: ('MESH:D006816', 'Disease') :: ['HD'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['Dexamethasone'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['Methotrexate']
@entity981 :: (MESH:D054198,Disease) :: ['ALL']
